

**BioRN Lounge with: Andreas Pahl, [Heidelberg Pharma](#)**

Topic: *“Amanitin-based Antibody-Drug-Conjugates as New Therapeutic Modalities for Cancer Therapy”*

**February 26, 2019, 7pm**

At the restaurant Urban Kitchen, Poststr. 36/5 in Heidelberg

**Register** by emailing to Sibylle Geilenberg: [sg@biorn.org](mailto:sg@biorn.org)



*Prof. Andreas Pahl*

**About:**

- Antigen-Targeted Amanitin-Conjugates (ATACs) represent a new class of ADCs using the payload Amanitin.
- This payload introduces a novel mode of action into oncology therapy, the inhibition of RNA polymerase II.
- The technology platform includes Amanitin supply, site-specific conjugation, demonstrated safety profile and biomarker.
- HDP-101 is the first ATAC directed against BCMA entering Phase I trials by the end of 2019

**Speaker: Prof. Andreas Pahl, Chief Scientific Officer, [Heidelberg Pharma](#).**

Professor Pahl has 25 years' experience in research and teaching and excellent expertise in biochemistry, pharmacology and toxicology. In 2008 he joined industry to pursue drug development for inflammatory and autoimmune diseases at Nycomed and Takeda. In 2012 he joined Heidelberg Pharma as the CSO extending his expertise to the area of oncology and antibody-drug conjugates. Since 2016 he is also CSO of Willex AG, the mother firm of Heidelberg Pharma. Recently, Willex AG was renamed to Heidelberg Pharma AG. Professor Pahl continues to be adjunct Professor for pharmacology and toxicology at the University of Erlangen-Nuremberg.